Glipizide Extended-Release Tablets
Brand names,
Glipizide Extended-Release Tablets
Analogs
Glipizide Extended-Release Tablets
Brand Names Mixture
Glipizide Extended-Release Tablets
Chemical_Formula
C21H27N5O4S
Glipizide Extended-Release Tablets
RX_link
http://www.rxlist.com/cgi/generic/glip.htm
Glipizide Extended-Release Tablets
fda sheet
Glipizide Extended-Release Tablets
msds (material safety sheet)
Glipizide Extended-Release Tablets
Synthesis Reference
Ambrogi, Logemann, U.S. Pat. 3,669,966 (1972)
Glipizide Extended-Release Tablets
Molecular Weight
444.548 g/mol
Glipizide Extended-Release Tablets
Melting Point
208-209 oC
Glipizide Extended-Release Tablets
H2O Solubility
37.2 mg/L
Glipizide Extended-Release Tablets
State
Solid
Glipizide Extended-Release Tablets
LogP
1.763
Glipizide Extended-Release Tablets
Dosage Forms
Immediate-release oral tablets; Extended-release oral tablets
Glipizide Extended-Release Tablets
Indication
For use as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (NIDDM; type II), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory.
Glipizide Extended-Release Tablets
Pharmacology
Glipizide, a second-generation sulfonylurea, is used with diet to lower blood glucose in patients with diabetes mellitus type II. The primary mode of action of glipizide in experimental animals appears to be the stimulation of insulin secretion from the beta cells of pancreatic islet tissue and is thus dependent on functioning beta cells in the pancreatic islets. In humans glipizide appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. In man, stimulation of insulin secretion by glipizide in response to a meal is undoubtedly of major importance. Fasting insulin levels are not elevated even on long-term glipizide administration, but the postprandial insulin response continues to be enhanced after at least 6 months of treatment. Some patients fail to respond initially, or gradually lose their responsiveness to sulfonylurea drugs, including glipizide.
Glipizide Extended-Release Tablets
Absorption
Gastrointestinal absorption is uniform, rapid, and essentially complete.
Glipizide Extended-Release Tablets
side effects and Toxicity
The acute oral toxicity was extremely low in all species tested (LD50 greater than 4 g/kg). Overdosage of sulfonylureas including glipizide can produce hypoglycemia.
Glipizide Extended-Release Tablets
Patient Information
Glipizide is a sulfonylurea used in patients with diabetes mellitus to lower blood sugar. Notify your physician if
you are pregnant or nursing. Do not change the dose or stop taking glipizide without talking with your physician.
Immediate-release glipizide tablets should be taken on an empty stomach, 30 minutes before a meal. Extended-release
glipizide tablets may be taken with food. Do not break, crush, or chew extended-release glipizide tablets. Patients
taking extended release glipizide tablets may notice something that looks like a tablet in their stool. This is the
leftover tablet after the medicine has been absorbed and is normal. Avoid drinking alcohol while taking this
medication. Alcohol may cause flushing, weakness, dizziness, a tingling sensation and headache. Avoid taking aspirin
with this medication. Notify your physician if you develop unexplained fever, sore throat, yellowing of the skin or
eyes, dark urine, or skin rash. Notify your physician if you develop fatigue, nausea, confusion, agitation, excessive
hunger, profuse sweating, numbness or tingling of lips, tongue or extremities (may indicate low blood sugar), or if
you develop excessive thirst or urination, or glucose or ketones in the urine or blood (may indicate high blood
sugar).
Glipizide Extended-Release Tablets
Organisms Affected
Humans and other mammals